<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5412">
  <stage>Registered</stage>
  <submitdate>8/07/2002</submitdate>
  <approvaldate>8/07/2002</approvaldate>
  <nctid>NCT00041275</nctid>
  <trial_identification>
    <studytitle>Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery</studytitle>
    <scientifictitle>Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NMRC-AHCC02</secondaryid>
    <secondaryid>CDR0000069460</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Liver Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - megestrol acetate

Treatment: drugs: megestrol acetate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival measured weekly</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as measured by EORTC quality of life instrument monthly</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatocellular carcinoma (HCC)

               -  Histologically confirmed OR

               -  Meets 2 of the following criteria:

                    -  Radiological evidence of HCC on CT scan, MRI, or ultrasound

                    -  Serum alpha-fetoprotein level at least 400 Âµg/L

                    -  Positive lipiodol retention

          -  Not amenable to surgery

        PATIENT CHARACTERISTICS:

        Age:

          -  20 to 100

        Performance status:

          -  ECOG 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 5.8 mg/dL

        Renal:

          -  Creatinine less than 1.7 mg/dL

        Other:

          -  Not pregnant

          -  No clinical encephalopathy

          -  No other malignancy within the past 5 years

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemoembolization for HCC

          -  No prior systemic chemotherapy for HCC

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

          -  No prior surgery for HCC

        Other:

          -  No prior percutaneous injection for HCC</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Bangladesh</country>
      <state>Dhaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Bali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Myanmar</country>
      <state>Yangon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Davao City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Ha Noi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Ho Chi Minh City</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>National Medical Research Council (NMRC), Singapore</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using megestrol
      may fight liver cancer by blocking the uptake of estrogen. It is not yet known if megestrol
      is an effective treatment for liver cancer.

      PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in treating
      patients who have liver cancer that cannot be removed by surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00041275</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pierce Chow, MD, PhD, MBBS, FRCS, FAMS</name>
      <address>National Cancer Centre, Singapore</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>